Eiger BioPharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview

Eiger Biopharmaceuticals

01/08/2023 03:07

* Eiger BioPharmaceuticals Inc  EIGR.OQ   EIGR.O  is
expected
to show a rise in quarterly revenue when it reports  results on
August 2 (estimated). 
    * The Palo Alto California-based  company is expected to
report  a
11.7% increase in revenue to $4.569 million from $4.09 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Eiger
BioPharmaceuticals
Inc is for a loss of 41 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Eiger
BioPharmaceuticals Inc is $4​, above​ its last closing price
of $0.68. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.48       -0.47      -0.52     Missed  -9.9
 Dec. 31 2023  -0.55       -0.54      -0.57     Missed  -4.9
 Sep. 30 2022  -0.52       -0.52      -0.62     Missed  -18.9​
 Jun. 30 2022  -0.61       -0.61      -0.51     Beat    15.9
 ​​Mar.        -0.65       -0.64      -0.64     Met     0.5
 31 2022                                                
 Dec. 31 2021  -0.67       -0.64      -0.64     Met     0​
 Sep. 30 2021  -0.56       -0.56      -0.65     Missed  -15.9
 Jun. 30 2021  -0.54       -0.55      -0.57     Missed  -4.2
 This summary was machine generated August 1 at 02:07 GMT.  All
figures in US dollars  unless otherwise stated